Jesus K. Yamamoto-Furusho

Prof. Jesus K. Yamamoto-Furusho

Inflammatory Bowel Disease Clinic, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Ciudad de México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2008 in World Journal of Gastroenterology
Verified
Journal Article
Open access
Fausto Sanchez-MunozFausto Sanchez-Munoz
Fausto Sanchez-Munoz
ADAaron Dominguez-Lopez
Aaron Dominguez-Lopez
Jesus K. Yamamoto-FurushoJesus K. Yamamoto-Furusho
Jesus K. Yamamoto-Furusho
Role of cytokines in inflammatory bowel disease

30 April 2025 in Nature
Verified
Journal Article
Open access
PDF file
LHLindsay Hracs
Lindsay Hracs
JWJoseph W. Windsor
Joseph W. Windsor
JGJulia Gorospe
Julia Gorospe
MCMichael Cummings
Michael Cummings
SCStephanie Coward
Stephanie Coward
GKGilaad Kaplan
Gilaad Kaplan
During the twentieth century, inflammatory bowel disease (IBD) was considered a disease of early industrialized regions in North America, Europe and Oceania1. At the turn of the twenty-first century, IBD incidence increased in newly industrialized and emerging regions in Africa, Asia and Latin America, while the prevalence in early industrialized regions continued to grow steadily2,3,4. Changes in the incidence and prevalence denote the evolution of IBD across four epidemiologic stages: stage 1 (emergence), characterized by low incidence and prevalence; stage 2 (acceleration in incidence), marked by rapidly rising incidence and low prevalence; and stage 3 (compounding prevalence), where the incidence decelerates, plateaus or declines while the prevalence steadily increases. A fourth stage (prevalence equilibrium) has been proposed in which the prevalence slope plateaus due to demographic shifts in an ageing IBD population, but it has not yet been evidenced. To date, these stages have remained theoretical, lacking specific numerical indicators to define transition points. Here, using real-world data from 522 population-based studies encompassing 82 global regions and spanning more than a century (1920–2024), we show spatiotemporal transitions across stages 1–3 and model stage 4 progression. Understanding the evolution of IBD across epidemiologic stages enables healthcare systems to better anticipate the future worldwide burden of IBD.

1 September 2015 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
Gabriela Fonseca-CamarilloGabriela Fonseca-Camarillo
Gabriela Fonseca-Camarillo
Jesus K. Yamamoto-FurushoJesus K. Yamamoto-Furusho
Jesus K. Yamamoto-Furusho
Inflammatory bowel diseases (IBD) include ulcerative colitis and Crohn's disease. The immune response in ulcerative colitis is different from the Crohn's disease. Accumulating evidence suggests that IBD results from an inappropriate inflammatory response to intestinal microbes in a genetically susceptible host. Several immunoregulatory abnormalities have been reported in patients with IBD, including the ratio of proinflammatory (tumor necrosis factor alpha, IL-6, IL-1-β) to immunoregulatory cytokines (IL-10, TGF-β, IL-35) and selective activation of T-helper (Th) lymphocyte subsets (Th1, Th2, Th9, Th17, and regulatory T cells). The purpose of this review is to show the immunoregulatory pathways (regulatory cells and cytokines) involved in IBD published in recent years.

1 October 2015 in Cytokine
Verified
Journal Article
Closed access
Gabriela Fonseca-CamarilloGabriela Fonseca-Camarillo
Gabriela Fonseca-Camarillo
JFJanette Furuzawa-Carballeda
Janette Furuzawa-Carballeda
Jesus K. Yamamoto-FurushoJesus K. Yamamoto-Furusho
Jesus K. Yamamoto-Furusho

1 January 2009 in World Journal of Gastroenterology
Verified
Journal Article
Open access
TRTatiana Sofía Rodríguez-Reyna
Tatiana Sofía Rodríguez-Reyna
CMCynthia Martínez-Reyes
Cynthia Martínez-Reyes
Jesus K. Yamamoto-FurushoJesus K. Yamamoto-Furusho
Jesus K. Yamamoto-Furusho
This article reviews the literature concerning rheumatic manifestations of inflammatory bowel disease (IBD), including common immune-mediated pathways, frequency, clinical course and therapy. Musculoskeletal complications are frequent and well-recognized manifestations in IBD, and affect up to 33% of patients with IBD. The strong link between the bowel and the osteo-articular system is suggested by many clinical and experimental observations, notably in HLA-B27 transgenic rats. The autoimmune pathogenic mechanisms shared by IBD and spondyloarthropathies include genetic susceptibility to abnormal antigen presentation, aberrant recognition of self, the presence of autoantibodies against specific antigens shared by the colon and other extra-colonic tissues, and increased intestinal permeability. The response against microorganisms may have an important role through molecular mimicry and other mechanisms. Rheumatic manifestations of IBD have been divided into peripheral arthritis, and axial involvement, including sacroiliitis, with or without spondylitis, similar to idiopathic ankylosing spondylitis. Other periarticular features can occur, including enthesopathy, tendonitis, clubbing, periostitis, and granulomatous lesions of joints and bones. Osteoporosis and osteomalacia secondary to IBD and iatrogenic complications can also occur. The management of the rheumatic manifestations of IBD consists of physical therapy in combination with local injection of corticosteroids and nonsteroidal anti-inflammatory drugs; caution is in order however, because of their possible harmful effects on intestinal integrity, permeability, and even on gut inflammation. Sulfasalazine, methotrexate, azathioprine, cyclosporine and leflunomide should be used for selected indications. In some cases, tumor necrosis factor-α blocking agents should be considered as first-line therapy.

1 November 2006 in Journal of Biological Chemistry
Verified
Journal Article
Open access
Jesus K. Yamamoto-FurushoJesus K. Yamamoto-Furusho
Jesus K. Yamamoto-Furusho
NBNicolas BARNICH
Nicolas BARNICH
RXRamnik Xavier
Ramnik Xavier
THTadakazu Hisamatsu
Tadakazu Hisamatsu
DPDaniel K. Podolsky
Daniel K. Podolsky
Centaurin beta1 (CENTB1), a GTPase-activating protein, is a member of the ADP-ribosylation factor family encoded by a gene located on the short arm of human chromosome 17. A yeast two-hybrid screen first suggested a direct interaction between CENTB1 and NOD2. Co-immunoprecipitation experiments confirmed direct interaction between CENTB1 and NOD2 and demonstrated similar interaction between CENTB1 and NOD1. We also demonstrate that endogenous CENTB1 interacts with endogenous NOD2 and NOD1 in SW480 and HT-29 intestinal epithelial cells. CENTB1 partially co-localized with NOD2 and NOD1 proteins in the cytoplasm of mammalian cells. CENTB1 expression in epithelial cells was highly induced by tumor necrosis factor alpha, interleukin 1beta, and the NOD1 and NOD2 ligands (gamma-d-glutamyl-meso-diaminopimelic acid and muramyl dipeptide, respectively). In addition, CENTB1 mRNA level is increased in the inflamed mucosa of patients with inflammatory bowel disease. Functionally, CENTB1 overexpression inhibited NOD1- and NOD2-dependent activation of NF-kappaB, whereas small inhibitory RNA against CENTB1 increased NF-kappaB activation following NOD1- or NOD2-mediated recognition of the bacterial components gamma-d-glutamyl-meso-diaminopimelic acid and muramyl dipeptide, respectively. In contrast, CENTB1 had no effect on NF-kappaB activation induced by Toll-like receptors. In conclusion, CENTB1 selectively down-regulates NF-kappaB activation via NODs pathways, creating a "feedback" loop and suggesting a novel role of CENTB1 in innate immune responses to bacteria and inflammatory responses.